<DOC>
	<DOCNO>NCT00150397</DOCNO>
	<brief_summary>This initial proof concept , phase study assess safety efficacy tofimilast chronic maintenance treatment adult persistent asthma</brief_summary>
	<brief_title>A Study Safety Efficacy Tofimilast Adult Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Mild moderate persistent asthma ( NAEPP/GINA Step 23 ) Reversibility albuterol least 12 % 200 mL Any significant comorbid disease , particularly cardiovascular Use maintenance therapy except short act bronchodilator Smoking history &gt; = 10 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>